6 reports

  • Pipeline: Mantle Cell Lymphoma
  • Marketed Drugs: Mantle Cell Lymphoma

Blood, ##(##), ##-## < DOI> ##. ##/ blood-2005-##-##< / DOI>.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.

SINCE ITS APPROVAL IN 1997, ROCHE' S RITUXAN HAS BEEN KEY IN THE NHL TREATMENT PARADIGM, AND FORMS THE BACKBONE OF CHEMOTHERAPY REGIMENS IN ALL THERAPY LINES FOR THE FOUR LARGEST B-CELL NHL INDICATIONS, DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), FOLLICULAR LYMPHOMA (FL), MARGINAL Z

  • Biosimilar
  • Lymphoma
  • Medical Biotechnology
  • Oncology
  • Amgen Inc.
  • ALL, CLL, DLBCL, NHL, FL, MCL
  • LIST OF TABLES

POST A FOLLOW-UP OF NINE MONTHS, THREE PATIENTS REPORTED PROGRESSION AS FOLLOWS: ONE PATIENT REPORTING CR PROGRESSED ONE MONTH AFTER INFUSION WITH AGGRESSIVE CD##-NEGATIVE TRANSFORMED LYMPHOMA ##. ##. ##. ##. ##.

  • Immunotherapy
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Amgen Inc.
  • lymphoma. The trial was registered with the U.S. National Institutes of Health.
  • PIPELINE BY AMGEN INC, H2 2018

As of November 2012, it was in Phase I mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma.

  • Immunotherapy
  • Lymphoma
  • World
  • Product Initiative
  • Amgen Inc.
  • Pipeline by Amgen Inc, H2 2018
  • Products under Development by Companies, H2 2018

From one-third to one-half of patients derived clinical benefit.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Amgen Inc.
  • Products under Development by Companies, H1 2018
  • Pipeline by Amgen Inc, H1 2018

From one-third to one-half of patients derived clinical benefit.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Amgen Inc.